Anafilaxia: atualizando as recomendações
do Practice Parameter 2023

Albertina Varandas Capelo; Alex Eustáquio de Lacerda; Jane da Silva; Renata Neiva Bittar; Marisa Rosimeire Ribeiro; Alexandra Sayuri Watanabe; Elaine Gagete Miranda-da-Silva; Ana Carolina D; Fabiana Andrade Oliveira; Mario Gueller; Nathalia Coelho Portilho Kelmann

doi:10.5935/2526-5393.20240035

Artigo de Revisão

Anafilaxia: atualizando as recomendações do Practice Parameter 2023

Anaphylaxis: updating Practice Parameter 2023 recommendations

Albertina Varandas Capelo; Alex Eustáquio de Lacerda; Jane da Silva; Renata Neiva Bittar; Marisa Rosimeire Ribeiro; Alexandra Sayuri Watanabe; Elaine Gagete Miranda-da-Silva; Ana Carolina D'Onofrio-Silva; Fabiana Andrade Oliveira; Mario Gueller; Nathalia Coelho Portilho Kelmann

http://dx.doi.org/10.5935/2526-5393.20240035 Arq Asma Alerg Imunol, vol.8, n3, p.225-234, 2024

PDF

Downloads: 0

Resumo

A anafilaxia é uma emergência médica potencialmente fatal que requer intervenção rápida e eficaz. Compreender e atualizar as práticas clínicas é crucial para garantir os melhores cuidados aos pacientes. Esta atualização baseada em evidências e experiência clínica de especialistas mostra uma discussão de aspectos focados em sete diferentes áreas com novas evidências e diferentes das diretrizes práticas anteriores. O texto resume desde aspectos do diagnóstico da anafilaxia, mastocitose, com destaque para o escore de indicação de biópsia de medula óssea e alfa triptasemia hereditária, investigação da anafilaxia perioperatória, influência dos betabloqueadores e inibidores da enzima de conversão da angiotensina, além das importantes indicações da prescrição dos autoinjetores de adrenalina, destacando-se aspectos práticos no manejo da autoprescrição.

Palavras-chave

Anafilaxia, epinefrina, diagnóstico, mastocitose.

Abstract

Anaphylaxis is a potentially life-threatening medical emergency that requires prompt and effective intervention. Understanding and updating clinical practices is crucial to ensure optimal patient care. This update is based on evidence and expert clinical experience and discusses aspects focusing on 7 different areas with new evidence and different from those of previous practice guidelines. The text summarizes aspects related to the diagnosis of anaphylaxis, mastocytosis, with emphasis on the indication rate of bone marrow biopsy and hereditary alpha tryptasemia, investigation of perioperative anaphylaxis, and influence of beta blockers and angiotensin-converting enzyme inhibitors, in addition to the important prescriptions for epinephrine autoinjectors, highlighting practical aspects in the management of self-medication.

Keywords

Anaphylaxis, epinephrine, diagnosis, mastocytosis.

Referências

1. Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al.; World Allergy Organization. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organ J. 2011 Feb;4(2):13-37. doi: 10.1097/WOX.0b013e318211496c.

2. Golden DBK, Wang J, Waserman S, Akin C, Campbell RL, Ellis AK, et al. Anaphylaxis: A 2023 practice parameter update. Ann Allergy Asthma Immunol. 2024;132(2):124-76.

3. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organization Journal. 2020 Oct 1;13(10).

4. Joint Task Force on Practice Parameters; American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. The diagnosis and management of anaphylaxis: an updated practice parameter. J Allergy Clin Immunol. 2005 Mar;115(3 Suppl 2):S483-523. doi: 10.1016/j.jaci.2005.01.010.

5. Alvarez-Twose I, González de Olano D, Sánchez-Muñoz L, Matito A, Esteban-López MI, Vega A, et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol. 2010 Jun;125(6):1269-1278.e2.

6. Lyons JJ. Hereditary alpha tryptasemia: genotyping and associated clinical features. Immunol Allergy Clin North Am. 2018;38(3):483-95.

7. Giannetti M, Silver J, Hufdhi R, Castells, MC. One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab. J Allergy Clin Immunol Pract. 2020;8:1431-5.

8. Gülen T, Akin C, Bonadonna P, Siebenhaar F, Broesby-Olsen S, Brockow K, et al. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. J Allergy Clin Immunol Pract. 2021 Nov;9(11):3918-28.

9. Greenhawt M, Gupta RS, Meadows JA, Pistiner M, Spergel JM, Camargo CA Jr, et al. Guiding Principles for the Recognition, Diagnosis, and Management of Infants with Anaphylaxis: An Expert Panel Consensus. J Allergy Clin Immunol Pract. 2019 Apr;7(4):1148-1156.e5.

10. Robinson LB, Arroyo AC, Faridi MK, Rudders S, Camargo Jr. CA. Trends in US Emergency Department visits for anaphylaxis among infants and toddlers: 2006-2015. J Allergy Clin Immunol Pract. 2021;9(5):1931-1938.e2.

11. Nassiri M, Babina M, Dolle S, Edenharter G, Rueff F, Worm M. Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming. J Allergy Clin Immunol. 2015;135(2):491-9.

12. Laroche D, Gomis P, Gallimidi E, Malinovsky JM, Mertes PM. Diagnostic value of histamine and tryptase concentrations in severe anaphylaxis with shock or cardiac arrest during anesthesia. Anesthesiology. 2014;121(2):272-9.

13. Gonzalez-Estrada A, Pien LC, Zell K, Wang XF, Lang DM. Antibiotics are an impor- tant identifiable cause of perioperative anaphylaxis in the United States. J Allergy Clin Immunol Pract. 2015;3(1). 101-5.e1.

14. Elwyn G, Frosch D, Rollnick S. Dual equipoise shared decision making: definitions for decision and behaviour support interventions. Implement Sci. 2009;4:75.

15. Waserman S, Cruickshank H, Hildebrand KJ, Mack D, Bantock L, Bingemann T, et al. Prevention and management of allergic reactions to food in child care centers and schools: practice guidelines. J Allergy Clin Immunol. 2021;147(5):1561-78.

16. Greenhawt M, MacGillivray F, Batty G, Said M, Weiss C. International study of risk-mitigating factors and in-flight allergic reactions to peanut and tree nut. J Allergy Clin Immunol Pract. 2013;1(2):186-94.

17. Lieberman JA, Wang J. Epinephrine in anaphylaxis: too little, too late. Curr Opin Allergy Clin Immunol. 2020;20(5):452-8.

18. Schworer SA, Kim EH. Sublingual immunotherapy for food allergy and its future directions. Immunotherapy. 2020;12(12):921-31.

19. Saleh-Langenberg J, Flokstra-de Blok BMJ, Goossens NJ, Kemna JC, van der Velde JL, Dubois AEJ. The compliance and burden of treatment with the epinephrine auto-injector in food-allergic adolescents. Pediatr Allergy Immunol. 2016;27 (1):28-34.

20. Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39(6):788-97.

21. Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol Pract. 2020;8(2):565-72.

22. Song TT, Lieberman P. Epinephrine auto-injector needle length: what is the ideal length? Curr Opin Allergy Clin Immunol. 2016;16(4):361-5.

23. Patel N, Chong KW, Yip AYG, Ierodiakonou D, Bartra J, Boyle RJ, et al. Use of multi ple epinephrine doses in anaphylaxis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2021;148(5):1307-15.

24. Lieberman JA, Wang J. Epinephrine in anaphylaxis: too little, too late. Curr Opin Allergy Clin Immunol. 2020;20(5):452-8.

25. Prince BT, Mikhail I, Stukus DR. Underuse of epinephrine for the treatment of anaphylaxis: missed opportunities. J Asthma Allergy. 2018;11:143-51.

26. PR Newswire. U.S. FDA approves Kaleo 's AUVI-Q (Epinephrine injection, USP) 0.1-mg auto-injector for life-threatening allergic reactions in infants and small children [Internet]. Available from: https://www.prnewswire.com/news-releases/us-fda-approves-kaleosauvi-q-epinephrine-injection-usp-01-mg-auto-injector-for-life-threatening-allergicreactions-in-infants-and-small-children-300559170.html. Accessed 09/15/2022.

27. Li LDX, Abrams EM, Lavine E, Hildebrand K, Mack DP. CSACI position statement: transition recommendations on existing epinephrine autoinjectors. Allergy Asthma Clin Immunol. 2021;17(1):130.

28. Wang J, Sicherer SH; SECTION ON ALLERGY AND IMMUNOLOGY. Guidance on Completing a Written Allergy and Anaphylaxis Emergency Plan. Pediatrics. 2017;139(3):e20164005.

29. American Academy of Allergy, Asthma & Immunology. Anaphlyaxis emergency action plan [Internet]. Available from: https://www.aaaai.org/aaaai/media/medialibrary/pdf%20documents/libraries/anaphylaxis-emergency-action-plan.pdf. Accessed 09/07/2022.

30. Casale TB, Wang J, Nowak-Wegrzyn A. Acute at home management of anaphylaxis during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8 (6):1795-7.

31. Casale TB, Wang J, Oppenheimer J, Nowak-Wegrzyn A. Acute at-home management of anaphylaxis: 911: what is the emergency? J Allergy Clin Immunol Pract. 2022;10(9):2274-9.

32. Cantrell FL, Cantrell P, Wen A, Gerona R. Epinephrine concentrations in EpiPens after the expiration date. Ann Intern Med. 2017;166(12):918-9.

33. Kassel L, Jones C, Turin R, Daly M, Mengesha A. Enantiomeric degradation of epinephrine in autoinjector products. J Allergy Clin Immunol Pract. 2022;10(9):2463-2465.e1.

Submetido em:
29/07/2024

Aceito em:
03/09/2024